Champions Oncology Analyst Ratings
Champions Oncology Analyst Ratings
While ratings are subjective and will change, the latest Champions Oncology (CSBR) rating was a maintained with a price target of $9.00 to $7.50. The current price Champions Oncology (CSBR) is trading at is $5.40, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/22/2023 | 38.89% | Roth MKM | $9 → $7.5 | Maintains | Buy |
| 03/15/2021 | 196.3% | Roth Capital | $13.5 → $16 | Maintains | Buy |
| 11/18/2019 | 103.7% | Benchmark | → $11 | Initiates Coverage On | → Speculative Buy |
| 09/20/2019 | 71.3% | Roth Capital | → $9.25 | Initiates Coverage On | → Buy |
| 07/24/2019 | — | Janney Montgomery Scott | Downgrades | Buy → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/22/2023 | 38.89% | 罗斯MKM | $9→$7.5 | 维护 | 买 |
| 03/15/2021 | 196.3% | 罗斯资本 | $13.5→$16 | 维护 | 买 |
| 2019年11月18日 | 103.7% | 基准 | →$11 | 开始承保 | →投机性买入 |
| 2019年09月20日 | 71.3% | 罗斯资本 | →$9.25 | 开始承保 | →购买 |
| 2019年07月24日 | - | 詹尼·蒙哥马利·斯科特 | 评级下调 | 购买→中性 |
What is the target price for Champions Oncology (CSBR)?
冠军肿瘤学(CSBR)的目标价格是多少？
The latest price target for Champions Oncology (NASDAQ: CSBR) was reported by Roth MKM on September 22, 2023. The analyst firm set a price target for $7.50 expecting CSBR to rise to within 12 months (a possible 38.89% upside). 1 analyst firms have reported ratings in the last year.
Roth MKM于2023年9月22日报道了冠军肿瘤学(纳斯达克：CSBR)的最新目标价。这家分析公司将目标价定为7.50美元，预计CSBR将在12个月内上涨至38.89%。1家分析公司在过去一年公布了评级。
What is the most recent analyst rating for Champions Oncology (CSBR)?
冠军肿瘤学(CSBR)的最新分析师评级是多少？
The latest analyst rating for Champions Oncology (NASDAQ: CSBR) was provided by Roth MKM, and Champions Oncology maintained their buy rating.
Roth MKM提供了对冠军肿瘤学(纳斯达克：CSBR)的最新分析师评级，冠军肿瘤学维持了买入评级。
When is the next analyst rating going to be posted or updated for Champions Oncology (CSBR)?
冠军肿瘤学(CSBR)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Champions Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Champions Oncology was filed on September 22, 2023 so you should expect the next rating to be made available sometime around September 22, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与冠军肿瘤公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。冠军肿瘤学的最后一次评级是在2023年9月22日提交的，所以你应该预计下一次评级将在2024年9月22日左右的某个时候提供。
Is the Analyst Rating Champions Oncology (CSBR) correct?
分析师评级冠军肿瘤学(CSBR)正确吗？
While ratings are subjective and will change, the latest Champions Oncology (CSBR) rating was a maintained with a price target of $9.00 to $7.50. The current price Champions Oncology (CSBR) is trading at is $5.40, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的冠军肿瘤学(CSBR)评级保持不变，目标价在9.00美元至7.50美元之间。冠军肿瘤学(CSBR)目前的交易价格为5.40美元，超出了分析师的预测范围。